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Abstract
Cutaneous squamous cell carcinoma (cSCC) is the most common type of skin tumour with the ability of metastatic
spread. It represents about 20% of all malignancies diagnosed worldwide each year. Despite increased knowledge
regarding the causes of skin cancer, the incidence of cSCC rises. The disease originates from epidermal keratinocytes,
but it may occur on all areas of the body. It has an invasive nature and the potential to metastasise. We report unusual
case of a giant metastatic desmoplastic cSCC of the gluteal region in a patient with previously resected desmoplastic
cSCC presenting 8 months later with multiple liver and lung metastases.
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To the Editor,
A 55-year-old man presented with gradually enlar-
ging pigmented skin lesion since many months. The
lesion was located on his left hip measuring 5 × 5 cm
and was surgically excised with a free margin of
healthy tissue. Histopathological examination of the
incisional biopsy showed the entire thickness of the
epithelium filled with atypical CK5+, TTF−, CK7−
and napsin A− keratinocytes. The tumour cells also
demonstrated hyperchromasia, nuclear pleomorphism
and increased number of mitosis, all consistent with
diagnosis of desmoplastic cutaneous squamous cell
carcinoma (cSCC) (Fig. 1a). The patient underwent
regular examinations, and his condition remained
stable for 8 months. After that period, he presented
with growing, inflamed mass in the gluteal region.
The metastatic work-up was positive and confirmed a
diagnosis of stage IV desmoplastic cSCC with liver
and lung metastases (Fig. 1b, c). Clinical and labora-
tory examinations did not reveal any signs of depleted
immune system. The patient refused further treatment
and unfortunately died after 2 months as a result of
tumour progression (Fig. 1d, e). The ultimate cause of
death was acute hepatic failure due to organ invasion
by neoplastic cells.
cSCC is the second most common form of non-me-
lanoma skin cancers and accounts for approximately
20% of all cutaneous malignancies. cSCC occurs in
men two to three times more frequently than it does
in women. Its global incidence varies geographically,
from 0.03 to 3.5 cases per 100,000 people per year
and seems to have increased over the past 30 years
by 50 and up to 200% [1, 2]. In contrast to basal cell
carcinoma, cSCC is aggressive malignancy and easily
metastasise via hematogenous and lymphogenous
routes. cSCC usually occurs on the upper portions of
the body, and the main symptom is a wart-like
growth that may have a rough, scaly surface with flat
reddish patches which occasionally bleeds or it has el-
evated growth with central depression that persists
for weeks and may rapidly increase in size. After the
treatment, the overall prognosis for the majority of
patients is excellent with an overall 5-year cure rate
of greater than 90 and 4.6% rate of recurrence [1, 2].
The metastatic potential has been estimated to range
from 2 to 5%, but this estimation should be consid-
ered with caution. The presence of distant metastatic
disease is associated with median survival of less than
2 years [1, 2]. The most prominent risk factors in-
clude exposure to sun or artificial ultraviolet radi-
ation, leukoplakia, Bowen’s disease, infection with
human papillomavirus, genetic factors such as muta-
tions in the MC1R gene, genetic defects in DNA repair,
therapy with immunosuppressive agents and advanced
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age [3–5]. Mutations in the suppressor gene p53 and RAS
gene as well as activation of EGFR are the most common
genetic abnormalities found in cSCCs [2, 4–6]. The differ-
ential diagnosis of cSCC may include keratoacanthoma,
basal cell carcinoma, amelanotic melanoma, fibrox-
anthoma, pseudoepitheliomatous hyperplasia or HPV-
induced papillomas [2]. Histopathologically, the subtypes
of cSCC include verrucous, spindle, desmoplastic,
acantholytic and adenosquamous form [2]. A biopsy or
excision of the lesion and the histologic examination in-
cluding immunohistochemistry, especially cytokeratin
AE1/AE3 immunostaining and 3D histology, should be
performed in all clinically suspicious lesions [7].
The cSCC is generally treated by surgical excision,
electrodessication and curettage. Non-surgical options for
the treatment include cryotherapy, topical chemotherapy,
photodynamic therapy, topical immune response modi-
fiers, radiotherapy and systemic chemotherapy [2]. In the
present case, the patient was initially diagnosed with des-
moplastic cSCC and treated with surgical resection in
combination with plastic reconstruction with preservation
of function and satisfactory cosmetic results. The remis-
sion lasted 8 months. After that period, he was diagnosed
with relapsed, poorly differentiated stage IV desmoplastic
cSCC which is clinically characterised by a highly infiltra-
tive growth and high metastatic potential (Fig. 1d, e). The
probable cause for relapse in this case was incomplete
clearence of the micrometastatic cancer cells that sur-
rounded the primary tumour. The palliative radiotherapy
and chemotherapy were not indicated according to
patient’s own conditions and wishes. However, stage
IV cSCC is responsive to a variety of different chemo-
therapeutic agents, but there is no established stand-
ard regimen. Among most common non-targeted
agents used are platin salts, 5-fluorouracil or taxanes
[2, 8, 9]. Polychemotherapy should be reserved for
patients requiring more aggressive management, while
otherwise, mono-chemotherapy should be considered
as a first-line treatment [2, 8, 9]. A chimeric im-
munoglobulin G1 monoclonal antibody cetuximab
has been reported in the literature as a successful
second-line option [9, 10]. Some tyrosine kinase
Fig. 1 Histopathological analysis showing desmoplastic cutaneous squamous cell carcinoma (a HE staging, original magnification ×200; b
cytokeratin AE1/AE3 immunostaining, original magnification ×200). Radiological evaluation revealed a metastatic involvement of the lung and the
liver (c, d). Clinical picture of the exulcerated, inflamed bleeding desmoplastic cutaneous squamous cell carcinoma of the left hip (e, f)
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inhibitors (gefitinib, dasatinib, erlotinib) as well as
different immunotherapy agents (anti-PD1 antibody,
pembrolizumab) demonstrated encouraging results in
the treatment of cSCC [11–16].
Finally, it is estimated that majority of all cSCC recur-
rences will develop within 2 years of the initial diagnosis
[17]. Therefore, all patients with cSCC should be followed
closely with regular follow-up schedule such as every
6 months depending on aggressiveness of the tumour and
clinical and histological criteria.
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